Pristane |
Catalog No.GC64748
One-Click Copy Product Info
|
Pristane is a colorless, odorless liquid primarily obtained from natural sources such as shark liver oil and is also found in small quantities in various plants and marine organisms.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1921-70-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Pristane is a colorless, odorless liquid primarily obtained from natural sources such as shark liver oil and is also found in small quantities in various plants and marine organisms[1]. Pristane is extensively used in medical research for its ability to induce autoimmune diseases in animal models, making it a valuable tool for studying the pathogenesis of conditions such as rheumatoid arthritis (RA) and lupus[4][5][6][7].
In vitro, Pristane treatment (5-400μM) on mouse strain-derived thymus lymphoma BW5147 cells for 48h induced apoptosis in a time- and dose-dependent manner via the mitochondrial pathway proved by the release of cytochrome c[2]. Pristane (1mM) stimulated bone marrow-derived macrophages (BMM) for 6 or 24h induced autophagy in BMMs and upregulated TLR3 expression by activating the STAT1-IRF1 pathway[3].
In vivo, BALB/c mice received a single i.p. injection of 0.5mL Pristane revealed the development of immune complex‐mediated glomerulonephritis, a hallmark of SLE. The autoimmune syndrome induced by Pristane in BALB/c mice resembles idiopathic SLE in humans including the development of anti-nuclear antibodies[4]. 0.5mL Pristane‐injected Swiss Jim Lambert mice developed severe glomerulonephritis characterized by proteinuria, mesangial proliferation, and glomerular immune complex deposits like in BALB/c mice. Unexpectedly, the predominant autoantibodies induced by Pristane in SJL mice were not those associated with Pristane-induced disease in BALB/c mice but, anti-ribosomal P, another lupus-related specificity. The autoantibodies were strongly reactive with the C-terminal 22 amino acids of the ribosomal P2 protein, indicating that they exhibited similar fine specificities to anti-P Abs in human SLE[6]. In contrast, C57BL/6J mice administrated with Pristane (0.5mL) via intraperitoneal injection exhibited milder nephritis, characterized by decreased levels of CD3 and CD4 in total leukocytes with upregulation of CD11b, Ly6G, Ly6C, F4/80, and CD86[6]. LEW rats administrated with 150μl of Pristane with an intradermal injection at the base of the tail developed severe arthritis with a sudden onset 2 to 3 weeks after treatment. By day 122, the clinically affected joints were severely compromised by the erosions and cartilage was almost completely lost[7].
References:
[1] Avigan J, Milne G W A, Highet R J. The occurrence of pristane and phytane in man and animals. 1967 Dec;144(1),0–131.
[2] Calvani N, Caricchio R, Tucci M, et al. Induction of apoptosis by the hydrocarbon oil pristane: implications for pristane-induced lupus. J Immunol. 2005 Oct 1;175(7):4777-82.
[3] Zhu W H, Xu J, Jiang C S, et al. Pristane induces autophagy in macrophages, promoting a STAT1-IRF1-TLR3 pathway and arthritis. Clin Immunol. 2017 Feb:175:56-68.
[4] Satoh M, Kumar A, Kanwar Y S, Reeves W H. Anti-nuclear antibody production and immune-complex glomerulonephritis in BALB/c mice treated with pristane. Proc Natl Acad Sci USA. 1995 Nov 21;92(24):10934-8.
[5] Satoh M, Hamilton KJ, Ajmani AK, et al. Autoantibodies toribosomal P antigens with immune complex glomerulonephritisin SJL mice treated with pristane. J Immunol. 1996;157(7):3200‐3206.
[6] Zhou Y L, Yang B B, Long H J, et al. Immune cell alterations in a pristane-induced lupus model in C57BL/6J mice. Rheumatology & Autoimmunity. 2024 Nov 27. 2767-1410
[7] Vingsbo C, Sahlstrand P, Brun J G, et al. Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. Am J Pathol. 1996 Nov;149(5):1675-83.
| Cell experiment [1]: | |
|
Cell lines |
marrow-derived macrophages NR8383 cells |
|
Preparation Method |
Bone marrow cell were isolated from DA rats and seeded at the density of 2 × 106/ml in L929-conditioned medium to differentiate into bone marrow-derived macrophages (BMM) using Cold Spring Harbor Protocols. After 7 days, BMM were stimulated by 1mM Pristane for 6 or 24h, and protein was isolated for gene expression detection. |
|
Reaction Conditions |
1mM; 6 or 24h |
|
Applications |
Pristane lead to increased expression of both LC3-II and TLR3 and induced autophagy in macrophages. |
| Animal experiment [2]: | |
|
Animal models |
C57Bl/10 mice |
|
Preparation Method |
Eight-week-old C57Bl/10 mice received a single intraperitoneal injection of 0.5mL of Pristane. Control mice received phosphate-buffered saline (PBS) injection. Mice were bled at 2 weeks after Pristane injection and monthly thereafter for serology and for antinuclear antibody (ANA). To characterize pulmonary disease, bronchoalveolar lavage (BAL) was carried out for total and differential cell count. Cytokines levels were checked for IL-2, IL-4, TNF-α, IFN-γ, IL-6 and IL-10. Lungs were examined by histopathology and electron microscopy. |
|
Dosage form |
0.5mL; i.p.; a single administration |
|
Applications |
All mice injected with Pristane developed a pulmonary capillaritis with perivascular infiltration with macrophages, neutrophils, lymphocytes and eosinophils. IL-6 and IL-10 were increased in BAL but levels of TNF-α, IFN-γ, IL-2 and IL-4 were not. |
|
References: |
|
| Cas No. | 1921-70-6 | SDF | |
| Formula | C19H40 | M.Wt | 268.52 |
| Solubility | DMSO : 100 mg/mL (372.41 mM; Need ultrasonic) | Storage | Store at -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.7241 mL | 18.6206 mL | 37.2412 mL |
| 5 mM | 744.8 μL | 3.7241 mL | 7.4482 mL |
| 10 mM | 372.4 μL | 1.8621 mL | 3.7241 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A liquid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)